Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LXRX
SellHot AirLexicon Pharmaceuticals, Inc. · Healthcare · United States · $1.0B · Avg Vol: $5M/d
28
StockRankGet insider-trade alerts
Q
31
V
24
M
63
P/E (TTM)
—
ROE
-40.2%
D/E
0.3x
Dividend %
—
COMPANY DESCRIPTION
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1M | 1.2M | 31.1M | 49.8M | 610.3% | 41.5M | 37.9M | 20.2M | -36.4% |
| EPS | -0.26 | -0.79 | -0.63 | -0.14 | — | -0.16 | -0.17 | -0.19 | — |
| Shares | 444.2M | 244.9M | 361.5M | 363.5M | -18.2% | 445.0M | — | — | — |
| Debt | 55.3M | 106.1M | 108.4M | 62.8M | 4.3% | 59.2M | — | — | — |
| Equity | 117.1M | 93.1M | 145.9M | 107.5M | -2.8% | — | — | — | — |
| Op CF | -88.9M | -161.9M | -178.8M | -67.9M | — | -65.0M | — | — | — |
| Inv CF | -71.1M | -49.9M | -15.4M | 113.0M | — | — | — | — | — |
| Fin CF | 142.2M | 188.0M | 238.3M | -48.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-13.7%
SMA 50SMA 200
Close
$2.02
RSI (14)
37.5
52W High
$2.68
From 52W High
0.8%
SCORE BREAKDOWN
Quality
31
ROIC
-32.1%23.4
ROE
-40.2%21.4
GP/Assets
19.3%43.4
Op. Margin
-3835.3%4.0
FCF/Assets
-24.2%17.5
Piotroski
431.0
Int. Cover
-6.3x25.7
D/E Ratio
0.34x37.9
Current Ratio
13.37x91.5
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-16.0x25.0
P/FCF
—N/A
P/B
5.7x24.6
P/S
24.0x14.4
Div Yield
—N/A
Momentum
63
52W High %
75%67.3
RS 6M
5%78.9
SMA 50/200
1.28x92.9
EPS Rev 4W
+7.6%87.0
EPS Rev 12W
—N/A
EPS Improve
-19%14.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.0B
P/E (Forward)
-11.8x
Gross Margin
86.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LXRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals, Inc.(you) | $1.0B | 28 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 27 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 28 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 29 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 26 | Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 26 | Sell |
| FTH | Faeth Therapeutics, Inc. | $874M | 30 | Sell |
| SLDB | Solid Biosciences Inc. | $1.0B | 33 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 23 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%